Gastroesophageal Cancer

CAP issues guideline to improve immunotherapy treatment

The CAP guideline is evidence-based and joins a small number of testing methods based on both the methodology and the status of the biomarker -- i.e., microsatellite testing and deficient mismatch repair process assessment. This stands in contrast to previous guidelines that focused on the cancer type or tumor origin.

August 4, 2022

Lucid launches 3 new test centers

The test centers are staffed with Lucid-employed nurse practitioners who use Lucid's EsoCheck cell collection device to collect surface esophageal cells. Then, the cells undergo Lucid's EsoGuard DNA esophageal test.

March 22, 2022

CAP seeks comment on guidelines for immunotherapy biomarker testing

The guidelines were created jointly by CAP with the following groups:

February 19, 2020